v3 Template
A

Alnylam Pharmaceuticals Inc.

Biopharmaceutical Cambridge, MA ~800 employees
Founded
--
Employees (Est.)
~800
40 leaders known
Total Funding
$1.3B
Funding Rounds
3
Last Funding
2025-12-17

About Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on pioneering RNA interference (RNAi) therapeutics, an innovative class of medicines that silence genes causing or contributing to diseases. Their mission is to develop transformational medicines to benefit as many patients as possible, driven by science and inspired by patient stories.

Products & Services

AMVUTTRA (vutrisiran):An RNAi therapeutic with an expanded indication granted by the FDA in the U.S., now available to treat a new group of patients.
Qfitlia (fitusiran):An RNAi therapeutic approved by the FDA in the U.S., developed in partnership with Sanofi, marking the 6th Alnylam-discovered approval.
General Product Listing:A range of RNAi therapeutics targeting various diseases, detailed under the product listing section on the website.

Specialties

RNA interference (RNAi) therapeutics Gene silencing Therapeutic areas including rare and prevalent diseases Drug delivery platforms

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Corporate Investment
T: -
FT: Corporate Investment
A: 250000000
MR: -
FA: 250 million
FAN: 250000000
D: 2025-12-17
FD: 2025-12-17
-
2 RT: Convertible Senior Notes
T: -
FT: Convertible Senior Notes
A: 575000000
MR: -
FA: $575 million
FAN: 575000000
D: 2025-09-09
FD: 2025-09-09
-
3 RT: Convertible Senior Notes
T: -
FT: Convertible Senior Notes
A: 500000000
MR: -
FA: $500 million
FAN: 500000000
D: 2025-09-08
FD: 2025-09-08
-
Corporate Investment Latest
2025-12-17
$250.0M
Convertible Senior Notes 2025-09-09
$575.0M
Convertible Senior Notes 2025-09-08
$500.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

P

Phillip Sharp

Institute Professor

D

Dennis Ausiello

MD

D

David Bartel

Professor of Biology

C

Carolyn R. Bertozzi

Anne T. and Robert M. Bass Professor of Chemistry

N

Nancy J. Brown

Dean of Yale School of Medicine and Professor of Internal Medicine

P

Priya S. Kishnani

C.L. and Su Chen Professor of Pediatrics and Professor of Molecular Genetics and Microbiology

View 37 more team members with Pro

Unlock Full Team Directory

Recent News

Alnylam Pharmaceuticals Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~800 employees (est.)
Locations
Cambridge, MA
San Francisco, USA
Chicago, Illinois

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro